Anteris Technologies Global Corp. — AGM Information 2008

Nov 11, 2008

==> picture [596 x 64] intentionally omitted <==

Innovative BioMedical Devices

Level 11, 225 St Georges Terrace bioMD Limited ABN 35 088 221 078 Perth, Western Australia 6000 PO Box 7209, Cloisters Square Western Australia 6850

Telephone (08) 9262 6777 Facsimile (08) 9322 3433

www.biomd.com.au

ANNOUNCEMENT TO THE AUSTRALIAN STOCK EXCHANGE

1 of 3 pages

12 November 2008

Company Announcements Office Australian Stock Exchange Limited 10[th] Floor, 20 Bond Street SYDNEY NSW 2000

Chairman’s Address

The Directors of bioMD Limited (the "Company") are pleased to announce the Chairman’s Address for the 5[th] Annual General Meeting of the company to be held today.

Yours faithfully

==> picture [79 x 59] intentionally omitted <==

Caroline Bentley Company Secretary

==> picture [596 x 42] intentionally omitted <==

==> picture [66 x 45] intentionally omitted <==

==> picture [32 x 56] intentionally omitted <==

CHAIRMAN’S ADDRESS

FIFTH Annual General Meeting of bioMD Ltd 12 November 2008 – The Somerset Hotel, 185 St George’s Terrace, Perth

OVERVIEW:

bioMD has achieved significant milestones during the past year. In fact, it was our Company’s most productive year since listing in March 2004.

During the period, we have

• Entered discussions with Global medical device companies to review our technology;

• Commenced a Phase II Human Clinical Trial in South Africa using CardioCel bovine pericardial patches in cardiovascular surgical procedures; and

• Commenced a further six collaborative research and development programs related to the heart valve, stem cell science and plastic surgery sectors.

The Board is hopeful that the coming year will have outcomes to reward shareholders, and we are conscious of the current global financial markets and the difficulty associated with this downturn.

I would like to reiterate the work done to date is significant and the ADAPT Tissue Engineering Process is proven to be a better alternative science in the global soft tissue repair sector. We have demonstrated this over the past two years, and the process of introducing it to the industry for which we have done this work is in train.

Turning to the financial results:

RESULTS:

The operating result of the Company for the year ended 30 June 2008 amounted to a loss of $1.2 million, which is significantly lower than the 2007 loss of $2.2 million, when a large impairment expense was recorded. We have focused on keeping administration costs to a minimum, and cash at bank as at year-end was $1.4 million.

I would like to acknowledge my fellow board members, our staff and the advisory team for their efforts during the year.

Thank you to our shareholders for your continuing interest in and support for the Company.

Looking forward, shareholders can anticipate bioMD entering an exciting phase as we pursue our principle objective to develop our ADAPT technology for use in broader surgical applications. The past year has been in a difficult market environment worldwide for biotechnology and healthcare companies so it is with optimism that we look forward to the next financial year and implementing our commercialisation strategy.